New Market - December 21, 2016
Orion plans for a new market authorisation
Orion Corporation has received favorable pharmacokinetic study results with combined salmeterol-fluticasone formulation of the Easyhaler product family and based on the results Orion is planning to apply for a marketing authorisation for the product in Europe. Orion currently estimates that the marketing authorisation application could be submitted in Europe during the first half of 2017. […]
Collaboration - December 20, 2016
Orion starts strategic collaboration
The Wisconsin Technology Innovation Initiative (Wi2) and Orion Corporation have announced a strategic collaboration in pursuit of new medicines for oncological diseases. Under the terms of the agreement, target proteins (modes of action) identified and initially validated at UW-Madison will be provided to Orion as a first step in establishing a research and development collaboration. […]
Agreement - January 15, 2014
Orion Corporation signs license agreement with Janssen Pharmaceuticals
Orion Corporation has entered into a license agreement with Janssen Pharmaceuticals for the development and commercialization of Orion’s novel, investigational alpha-2c adrenoceptor antagonists for the symptoms of Alzheimer’s disease, including a clinical phase compound ORM-12741. According to the agreement, Orion will receive an upfront payment of USD 31 million and is eligible to receive milestone […]
Agreement - November 15, 2013
Orion licenses the levosimendan injection rights in the USA and Canada to Phyxius
Orion Corporation and Phyxius Pharma have entered into a licensing agreement for levosimendan injection. According to the agreement Phyxius Pharma will develop and commercialize levosimendan in the USA and Canada for a new cardiovascular indication, prevention of Low Cardiac Output Syndrome (LCOS) in cardiac surgery patients. LCOS is a common complication in patients undergoing cardiac […]
